FDA Adverse Event Draft Guidance Would Restrict "Well Tolerated" Claims
Executive Summary
FDA would restrict the use of nonspecific safety claims such as "well tolerated" under its draft guidance on adverse event labeling.
You may also be interested in...
Confidence Intervals Favored Over P-Values In FDA Clinical Studies Guidance
P-values are not an adequate measure of uncertainty in describing the clinical outcome of a treatment relative to a comparator, FDA maintains in a draft guidance on the Clinical Studies section of labeling.
Confidence Intervals Favored Over P-Values In FDA Clinical Studies Guidance
P-values are not an adequate measure of uncertainty in describing the clinical outcome of a treatment relative to a comparator, FDA maintains in a draft guidance on the Clinical Studies section of labeling.
Indication, Warning Summaries In Labeling "Highlights" - FDA Rule
The new Highlights section of labeling under FDA's proposed labeling rule would feature a summary of the product's indication rather than the indication verbatim.